246250 — SLS Bio Co Balance Sheet
0.000.00%
- KR₩34bn
- KR₩27bn
- KR₩9bn
Annual balance sheet for SLS Bio Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 677 | 90.8 | 1,390 | 2,548 | 9,355 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1,239 | 1,722 | 2,059 | 3,035 | 2,057 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 1,942 | 2,146 | 3,758 | 6,058 | 11,751 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 5,505 | 5,312 | 4,790 | 4,084 | 4,173 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 11,083 | 10,135 | 10,506 | 11,753 | 17,838 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3,216 | 2,984 | 3,395 | 2,043 | 1,736 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 6,942 | 6,597 | 6,782 | 5,048 | 4,371 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 4,141 | 3,538 | 3,724 | 6,705 | 13,466 |
Total Liabilities & Shareholders' Equity | 11,083 | 10,135 | 10,506 | 11,753 | 17,838 |
Total Common Shares Outstanding |